PDF herunterladen
Thromb Haemost 1987; 58(03): 879-883
DOI: 10.1055/s-0038-1646007
Original Article
Schattauer GmbH Stuttgart

Measurement of Low Molecular Weight Heparin Ex Vivo Activities in Clinical Laboratories Using Various Anti-Xa Assays: Interlaboratory Variability and Requirement for an Agreed Low Molecular Weight Heparin Standard

P Sié
1   The Haemostasis laboratories, Hôpital Purpan, Toulouse, France
*   who coordinated the study
,
M F Aillaud
2   The CHU La Timone, Marseille, Boulogne, France
,
D de Prost
3   The CHU Xavier-Bichat, Paris, Boulogne, France
,
C Droullé
4   The CHU Robert-Debré, Reims, Boulogne, France
,
F Forestier
5   The Hôpital Notre-Dame de Bon-Secours, Paris, Boulogne, France
,
P Guedj
6   The Hôpital de la Conception, Marseille, Boulogne, France
,
I Juhan-Vague
2   The CHU La Timone, Marseille, Boulogne, France
,
B Polack
7   The CHRU, Grenoble, Boulogne, France
,
G Potron
4   The CHU Robert-Debré, Reims, Boulogne, France
,
M Roncato
8   The Hôpital Broussais, Paris, Boulogne, France
,
J Roussi
9   The Hôpital Ambroise-Paré, Boulogne, France
,
J Sampol
6   The Hôpital de la Conception, Marseille, Boulogne, France
,
M Aiach
8   The Hôpital Broussais, Paris, Boulogne, France
*   who coordinated the study
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 12. März 1987

Accepted after revision 02. Juni 1987

Publikationsdatum:
28. Juni 2018 (online)

  als PDF herunterladen  Lizenzen und Reprints

Summary

The only sensitive and convenient assay to assess the biological activity of low molecular weight heparins (LMWHs) is based on the potentiation of activated factor Xa inhibition. Several procedures for measuring the socalled anti Xa activity have been proposed. In this collaborative study including eight laboratories, we have used four different assays (three amidolytic and one clotting based methods) for measuring the anti Xa activity of ex vivo samples obtained after injecting three different LMWHs. The dispersion of the results obtained by calibration against standard heparin could be reduced by using any of the three LMWHs for calibration. A coefficient of variation less than 0.20 between values obtained in different laboratories using a variety of methods seems acceptable. However it is necessary to refer to a common international standard for expressing the results in units and to define, for each of the three products, the therapeutic range.

Keywords

Ex vivo anti-Xa activity - LMW heparins
 

  • References

  • 1 Kakkar VV, Murray W JG. Efficacy and safety of low-molecular- weight heparin (CY 216) in pieventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedGoogle Scholar
  • 2 Turpie A GG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. New Engl J Med 1986; 315: 925-929
    CrossrefPubMedGoogle Scholar
  • 3 Schmitz-Huebner U, Riischemeyer C, Schulte H, Van de Loo J. Influence of low molecular weight heparin on the hemostatic system after abdominal surgery. Thromb Haemostas 1985; 53: 297-300
    PubMedGoogle Scholar
  • 4 Massonet-Castel S, Pelissier E, Dreyfus G, Deloche A, Abry B, Guibourt P, Terrier E, Passelecq J, Jaulmes B, Carpentier A. Low molecular weight heparin in extracorporeal circulation. Lancet 1984; 1: 1182-1183
    PubMedGoogle Scholar
  • 5 Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemostas 1985; 54: 813-817
    PubMedGoogle Scholar
  • 6 Huet Y, Gouhault-Heilmann M, Brun-Buisson G, Contant G, Brun-Ney D. Low molecular weight heparin fractions as anticoagulant therapy in pulmonary embolism in man. Circulation 1984; 70: 96
    PubMedGoogle Scholar
  • 7 Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahle M, Haugen K, Loerum F, Schell B, Sortland O, Vinge B. Subcutaneous heparin treatment of deep venous thrombosis: comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 suppl. (02) 30-37
    PubMedGoogle Scholar
  • 8 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
    CrossrefPubMedGoogle Scholar
  • 9 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedGoogle Scholar
  • 10 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
    CrossrefPubMedGoogle Scholar
  • 11 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular weight heparins: a collaborative study. Thromb Haemostas 1985; 54: 675-679
    PubMedGoogle Scholar
  • 12 Teien A, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
    CrossrefPubMedGoogle Scholar
  • 13 Denson K WE, Bonnar J. The measurement of heparin: a method based on the potentiation of anti-factor Xa. Thromb Diath Haemorrh 1973; 30: 471-479
    PubMedGoogle Scholar
  • 14 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl V. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
    CrossrefPubMedGoogle Scholar
  • 15 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assavs of plasma heparin. Br J Haemorrh 1973; 30: 471-479
    PubMedGoogle Scholar
  • 16 Barrowcliffe TW, Curtis AD, Thomas DP. Establishment of a low molecular weight heparin standard: Report of the international collaborative study. To be published
    PubMedGoogle Scholar